IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

GIUGLIANO, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.116
AS - Asia 1.312
NA - Nord America 921
SA - Sud America 173
AF - Africa 45
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.588
Salva come PNG Salva come JPEG
Nazione #
DE - Germania 1.261
US - Stati Uniti d'America 855
CN - Cina 461
SG - Singapore 378
IT - Italia 245
SE - Svezia 130
BR - Brasile 125
HK - Hong Kong 119
IN - India 110
FR - Francia 88
GB - Regno Unito 86
RU - Federazione Russa 72
JP - Giappone 48
NL - Olanda 45
VN - Vietnam 43
ES - Italia 40
CA - Canada 34
ID - Indonesia 33
IE - Irlanda 31
MX - Messico 26
CH - Svizzera 25
KR - Corea 25
TR - Turchia 25
PL - Polonia 20
AR - Argentina 19
FI - Finlandia 18
TW - Taiwan 18
BE - Belgio 14
AU - Australia 11
CO - Colombia 10
CI - Costa d'Avorio 9
EG - Egitto 9
PK - Pakistan 8
LB - Libano 7
NZ - Nuova Zelanda 7
TN - Tunisia 7
GR - Grecia 6
PT - Portogallo 6
VE - Venezuela 6
BD - Bangladesh 5
IQ - Iraq 5
IR - Iran 5
PH - Filippine 5
AT - Austria 4
CL - Cile 4
DZ - Algeria 4
MA - Marocco 4
PE - Perù 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
HR - Croazia 3
HU - Ungheria 3
JM - Giamaica 3
KE - Kenya 3
MY - Malesia 3
SD - Sudan 3
TH - Thailandia 3
CZ - Repubblica Ceca 2
EC - Ecuador 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
UA - Ucraina 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
EE - Estonia 1
GI - Gibilterra 1
GU - Guam 1
IL - Israele 1
JO - Giordania 1
LU - Lussemburgo 1
LV - Lettonia 1
NA - Namibia 1
NI - Nicaragua 1
OM - Oman 1
QA - Qatar 1
SC - Seychelles 1
SR - Suriname 1
SV - El Salvador 1
UY - Uruguay 1
Totale 4.588
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 1.186
Singapore 181
Ashburn 163
Hong Kong 98
Hefei 88
Milan 71
Dallas 70
Santa Clara 62
Beijing 57
Chandler 57
Los Angeles 38
Bengaluru 34
Shanghai 28
Dublin 27
Rome 27
Council Bluffs 25
Hyderabad 23
New York 22
Munich 20
Paris 20
Tokyo 19
Jakarta 18
Buffalo 17
Southend 17
Boardman 16
Boston 16
São Paulo 16
Moscow 15
Cangzhou 13
London 13
Chennai 12
Hanoi 12
Cambridge 11
Florence 11
Guangzhou 11
Shenzhen 11
Montreal 10
Nuremberg 10
Princeton 10
Abidjan 9
Bologna 9
Chicago 9
Gdansk 9
Rio de Janeiro 9
Taipei 9
Toronto 9
Barcelona 8
Cairo 8
Düsseldorf 8
Fuzhou 8
Helsinki 8
Madrid 8
Mexico City 8
Seoul 8
Ann Arbor 7
Brussels 7
Buenos Aires 7
Denver 7
Hangzhou 7
Ho Chi Minh City 7
Oklahoma City 7
Oldham 7
Istanbul 6
Nanjing 6
Putnam Valley 6
Quanzhou 6
Roubaix 6
Valencia 6
Ahmedabad 5
Anacapri 5
Cologne 5
Lanester 5
Lappeenranta 5
Naples 5
Portsmouth 5
Rho 5
Stockholm 5
Tunis 5
Vancouver 5
Ancona 4
Aracaju 4
Atlanta 4
Bogotá 4
Brasília 4
Brescia 4
Changsha 4
Chapel Hill 4
Charlotte 4
Cuauhtémoc 4
Fortaleza 4
Kaohsiung 4
Karachi 4
Lausanne 4
Porto Alegre 4
Salvador 4
San Jose 4
Santiago 4
Seattle 4
Seodaemun-gu 4
Sydney 4
Totale 2.913
Salva come PNG Salva come JPEG
Nome #
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 687
Margetuximab for the treatment of HER2-positive metastatic breast cancer 478
Systemic Treatment of Ductal Carcinoma In Situ of the Breast 189
Auto-immune toxiity of Sars-Cov2 vaccine in patients with thymic epithelial tumours: a prospective analysis from the tyme net 187
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 187
Bystander effect of antibody-drug conjugates: fact or fiction? 184
Evolution of low HER2 expression between early and advanced-stage breast cancer 161
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management 160
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution 156
First line treatment of BRAF mutated advanced melanoma: Does one size fit all? 152
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives 146
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 144
HER2-Low Breast Cancer: a New Subtype? 142
Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies 141
Clinical development and current role of margetuximab for the treatment of breast cancer 140
Characterization of low HER2 expressions in de-novo metastatic breast cancer 139
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 135
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 129
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis 124
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 122
Harmonizing PD-L1 testing in metastatic triple negative breast cancer 121
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology 109
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases 109
Antibody–drug conjugates for the treatment of breast cancer 103
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology 85
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 84
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 60
PARP Inhibitors for Breast Cancer Treatment 57
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 36
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies 5
Totale 4.672
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.958
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.958
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202129 0 0 0 0 0 0 0 0 1 5 5 18
2021/2022155 14 10 8 4 7 6 2 20 28 18 16 22
2022/2023429 22 32 48 39 41 41 22 32 49 22 52 29
2023/20241.405 47 47 42 68 110 76 202 162 88 158 192 213
2024/20251.522 166 189 158 160 107 63 34 119 76 129 131 190
2025/20261.132 291 214 266 190 159 12 0 0 0 0 0 0
Totale 4.672